Novo Nordisk lifts 2026 outlook after strong second quarter with 7% adjusted sales growth at CER.

Novo Nordisk reported second quarter adjusted sales growth of 7% and adjusted operating profit growth of 11%, both at constant exchange rates (CER). Citing stronger expectations for its GLP-1 products, the company raised its full-year 2026 guidance for both adjusted sales and operating profit growth.

Key Highlights

• Q2 Adjusted Sales: Increased 7% at CER to DKK 78,488 million.
• Q2 Adjusted Operating Profit: Grew 11% at CER to DKK 33,389 million, excluding a DKK 6.3 billion impairment charge.
• Raised 2026 Sales Outlook: Full-year adjusted sales growth guidance was lifted to 0% to -6% at CER, from a prior range of -4% to -12%.
• Raised 2026 Profit Outlook: Full-year adjusted operating profit growth guidance was also raised to 0% to -6% at CER, from -4% to -12%.